Share Price and Basic Stock Data
Last Updated: January 24, 2026, 4:49 pm
| PEG Ratio | 16.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Syngene International Ltd operates in the miscellaneous sector, with a current share price of ₹601 and a market capitalization of ₹24,231 Cr. The company reported a total revenue of ₹3,193 Cr for the fiscal year ending March 2023, marking a significant increase from ₹2,604 Cr in March 2022. Revenue continued to rise, reaching ₹3,489 Cr in March 2024 and ₹3,642 Cr in March 2025, reflecting a robust growth trajectory. The trailing twelve months (TTM) revenue stood at ₹3,747 Cr, indicating sustained performance. Quarterly sales exhibited volatility, peaking at ₹994 Cr in March 2023, followed by a decline in subsequent quarters, with the latest reported sales at ₹910 Cr in September 2023. The operating profit margin (OPM) for the same period was recorded at 22%, showcasing the company’s operational efficiency. Overall, Syngene’s revenue trends illustrate a consistent upward movement, aligning with industry growth patterns, although the fluctuations in quarterly sales suggest potential seasonality or demand variability.
Profitability and Efficiency Metrics
Syngene International’s profitability metrics reflect a solid operational foundation. The net profit for the fiscal year ending March 2023 was ₹464 Cr, increasing to ₹496 Cr in March 2025, showcasing a stable profit growth despite fluctuations in quarterly performance. The reported net profit margin stood at 13.62% for March 2025, slightly declining from 14.54% in March 2023, indicating effective cost management amidst rising expenses. The company achieved an impressive return on equity (ROE) of 10.49% and a return on capital employed (ROCE) of 12.61% as of March 2025, both of which are competitive compared to typical sector averages. The interest coverage ratio (ICR) was recorded at 20.97x, indicating strong earnings relative to interest obligations, which enhances financial stability. However, the cash conversion cycle (CCC) at -23 days reflects efficient working capital management, although it has shown variability over recent years, suggesting fluctuations in operational efficiency.
Balance Sheet Strength and Financial Ratios
Syngene’s balance sheet demonstrates a healthy financial position, with total assets reported at ₹6,796 Cr as of March 2025. The company’s reserves have significantly increased, reaching ₹4,332 Cr, up from ₹3,217 Cr in March 2023, reflecting strong retained earnings and growth potential. Borrowings stood at ₹582 Cr, indicating a low leverage ratio with a debt-to-equity ratio of 0.02x, which is favorable compared to industry norms. The current ratio of 1.64x and quick ratio of 1.53x suggest adequate liquidity to meet short-term obligations. Furthermore, the price-to-book value (P/BV) ratio was recorded at 6.18x, indicating a premium valuation compared to book value. However, the inventory turnover ratio of 18.49x indicates efficient inventory management, suggesting that the company is adept at converting inventory into sales quickly. Overall, Syngene’s balance sheet reflects a strong financial foundation with ample liquidity and low debt levels.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Syngene International Ltd indicates a stable investor base, with promoters holding 52.68% of the shares as of September 2025, down from 64.86% in December 2022. This decline may reflect a strategic move to diversify ownership or increase liquidity in the market. Foreign institutional investors (FIIs) accounted for 16.31% of the shareholding, down from a peak of 23.31% in March 2023, indicating fluctuating confidence among foreign investors. Domestic institutional investors (DIIs) have increased their stake to 24.62%, suggesting growing domestic interest and confidence in the company’s future. The total number of shareholders stood at 1,36,061, indicating a broad retail investor base. This diverse ownership structure may enhance market stability and investor confidence, crucial for long-term growth. However, the reduction in promoter holdings could also raise concerns regarding control and strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, Syngene International Ltd is positioned for continued growth, supported by its robust revenue trends and strong profitability metrics. However, challenges such as fluctuating quarterly sales and a declining net profit margin may pose risks to sustained performance. The company’s low leverage provides a cushion against financial distress, yet it must navigate potential market volatility and competition effectively. The ongoing strategic adjustments in shareholding patterns could impact investor sentiment and future funding strategies. Strengths include a solid balance sheet, efficient operational metrics, and a diverse investor base, which collectively support growth prospects. Conversely, risks include economic fluctuations affecting demand and the potential for increasing operational costs. In this context, Syngene’s ability to manage these dynamics will be critical in maintaining its competitive edge and achieving long-term objectives.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mipco Seamless Rings (Gujarat) Ltd | 9.68 Cr. | 27.0 | 37.4/22.0 | 3.71 | 0.00 % | % | % | 10.0 | |
| MPIL Corporation Ltd | 23.3 Cr. | 408 | 787/330 | 242 | 0.11 % | 12.8 % | 15.5 % | 10.0 | |
| FGP Ltd | 9.58 Cr. | 8.05 | 13.7/7.32 | 3.09 | 0.00 % | 0.00 % | 0.89 % | 10.0 | |
| Logica Infoway Ltd | 358 Cr. | 201 | 267/173 | 26.1 | 53.0 | 0.00 % | 14.3 % | 14.1 % | 10.0 |
| CRP Risk Management Ltd | 10.8 Cr. | 6.18 | 9.49/5.61 | 34.6 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| Industry Average | 7,244.75 Cr | 252.69 | 39.80 | 104.34 | 0.04% | 48.42% | 7.44% | 9.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 768 | 786 | 994 | 808 | 910 | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 | 911 |
| Expenses | 552 | 555 | 680 | 596 | 656 | 622 | 600 | 620 | 646 | 660 | 674 | 668 | 711 |
| Operating Profit | 216 | 231 | 314 | 212 | 254 | 232 | 317 | 170 | 245 | 284 | 344 | 206 | 200 |
| OPM % | 28% | 29% | 32% | 26% | 28% | 27% | 35% | 22% | 27% | 30% | 34% | 24% | 22% |
| Other Income | 15 | 17 | 23 | 24 | 14 | 26 | 16 | 50 | 16 | 18 | 19 | 18 | 15 |
| Interest | 12 | 14 | 10 | 10 | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 | 13 |
| Depreciation | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 | 116 |
| Profit before tax | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 240 | 101 | 85 |
| Tax % | 22% | 22% | 23% | 24% | 23% | 19% | 10% | 25% | 23% | 27% | 24% | 14% | 21% |
| Net Profit | 102 | 110 | 179 | 93 | 116 | 112 | 189 | 76 | 106 | 131 | 183 | 87 | 67 |
| EPS in Rs | 2.54 | 2.73 | 4.45 | 2.32 | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.55 | 2.15 | 1.67 |
Last Updated: January 10, 2026, 10:33 am
Below is a detailed analysis of the quarterly data for Syngene International Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 911.00 Cr.. The value appears strong and on an upward trend. It has increased from 874.00 Cr. (Jun 2025) to 911.00 Cr., marking an increase of 37.00 Cr..
- For Expenses, as of Sep 2025, the value is 711.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 668.00 Cr. (Jun 2025) to 711.00 Cr., marking an increase of 43.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 200.00 Cr.. The value appears to be declining and may need further review. It has decreased from 206.00 Cr. (Jun 2025) to 200.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Sep 2025, the value is 22.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Jun 2025) to 22.00%, marking a decrease of 2.00%.
- For Other Income, as of Sep 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Jun 2025) to 15.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 13.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.00 Cr. (Jun 2025) to 13.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 111.00 Cr. (Jun 2025) to 116.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 85.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Jun 2025) to 85.00 Cr., marking a decrease of 16.00 Cr..
- For Tax %, as of Sep 2025, the value is 21.00%. The value appears to be increasing, which may not be favorable. It has increased from 14.00% (Jun 2025) to 21.00%, marking an increase of 7.00%.
- For Net Profit, as of Sep 2025, the value is 67.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Jun 2025) to 67.00 Cr., marking a decrease of 20.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.67. The value appears to be declining and may need further review. It has decreased from 2.15 (Jun 2025) to 1.67, marking a decrease of 0.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 | 3,747 |
| Expenses | 949 | 1,289 | 1,394 | 1,507 | 1,806 | 2,251 | 2,472 | 2,598 | 2,714 |
| Operating Profit | 474 | 537 | 618 | 678 | 798 | 942 | 1,017 | 1,045 | 1,033 |
| OPM % | 33% | 29% | 31% | 31% | 31% | 30% | 29% | 29% | 28% |
| Other Income | 53 | 75 | 153 | 94 | 20 | 63 | 77 | 101 | 70 |
| Interest | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 53 | 53 |
| Depreciation | 131 | 164 | 219 | 274 | 310 | 366 | 426 | 433 | 442 |
| Profit before tax | 372 | 415 | 517 | 469 | 484 | 594 | 621 | 660 | 608 |
| Tax % | 18% | 20% | 20% | 14% | 18% | 22% | 18% | 25% | |
| Net Profit | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 496 | 468 |
| EPS in Rs | 7.64 | 8.29 | 10.30 | 10.12 | 9.88 | 11.57 | 12.69 | 12.33 | 11.63 |
| Dividend Payout % | 7% | 3% | 0% | 0% | 10% | 11% | 10% | 10% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 8.85% | 24.10% | -1.70% | -2.22% | 17.17% | 9.91% | -2.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 15.24% | -25.80% | -0.52% | 19.39% | -7.26% | -12.66% |
Syngene International Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 4% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 5% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: December 4, 2025, 2:04 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 | 403 |
| Reserves | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 | 4,324 | 4,332 |
| Borrowings | 787 | 813 | 773 | 893 | 1,022 | 815 | 555 | 578 | 582 |
| Other Liabilities | 681 | 922 | 1,214 | 1,169 | 1,245 | 1,398 | 1,339 | 1,491 | 1,226 |
| Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 6,542 |
| Fixed Assets | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 | 2,802 | 3,049 |
| CWIP | 155 | 274 | 234 | 237 | 346 | 177 | 838 | 1,266 | 989 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 918 | 548 | 647 | 547 |
| Other Assets | 1,846 | 1,337 | 1,133 | 1,743 | 1,790 | 2,069 | 1,916 | 2,081 | 1,957 |
| Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 6,542 |
Below is a detailed analysis of the balance sheet data for Syngene International Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 403.00 Cr.. The value appears strong and on an upward trend. It has increased from 402.00 Cr. (Mar 2025) to 403.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,332.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,324.00 Cr. (Mar 2025) to 4,332.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Sep 2025, the value is 582.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 578.00 Cr. (Mar 2025) to 582.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,226.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,491.00 Cr. (Mar 2025) to 1,226.00 Cr., marking a decrease of 265.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be improving (decreasing). It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,049.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,802.00 Cr. (Mar 2025) to 3,049.00 Cr., marking an increase of 247.00 Cr..
- For CWIP, as of Sep 2025, the value is 989.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,266.00 Cr. (Mar 2025) to 989.00 Cr., marking a decrease of 277.00 Cr..
- For Investments, as of Sep 2025, the value is 547.00 Cr.. The value appears to be declining and may need further review. It has decreased from 647.00 Cr. (Mar 2025) to 547.00 Cr., marking a decrease of 100.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,957.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,081.00 Cr. (Mar 2025) to 1,957.00 Cr., marking a decrease of 124.00 Cr..
- For Total Assets, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..
Notably, the Reserves (4,332.00 Cr.) exceed the Borrowings (582.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -313.00 | -276.00 | -155.00 | -215.00 | 797.00 | 127.00 | -554.00 | -577.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 68 | 72 | 79 | 71 | 61 | 46 | 53 |
| Inventory Days | 82 | 30 | 18 | 41 | 87 | 141 | 94 | 60 |
| Days Payable | 195 | 154 | 156 | 167 | 113 | 109 | 100 | 136 |
| Cash Conversion Cycle | -44 | -56 | -66 | -47 | 45 | 92 | 40 | -23 |
| Working Capital Days | -48 | -103 | -172 | -66 | -43 | -14 | -27 | -51 |
| ROCE % | 17% | 17% | 14% | 13% | 15% | 15% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Large & Midcap Fund | 5,189,854 | 0.77 | 337.86 | 4,555,277 | 2026-01-25 06:22:29 | 13.93% |
| Nippon India Small Cap Fund | 4,906,326 | 0.47 | 319.4 | 4,592,970 | 2026-01-25 02:17:23 | 6.82% |
| Mirae Asset Focused Fund | 4,207,261 | 3.52 | 273.89 | 4,326,512 | 2026-01-26 00:59:00 | -2.76% |
| Nippon India Focused Fund | 4,008,177 | 2.97 | 260.93 | 3,708,177 | 2025-12-14 09:10:17 | 8.09% |
| Mirae Asset ELSS Tax Saver Fund | 3,855,733 | 0.92 | 251.01 | 3,387,681 | 2025-12-15 00:57:48 | 13.82% |
| ICICI Prudential ELSS Tax Saver Fund | 3,770,138 | 1.66 | 245.44 | 3,400,267 | 2025-12-08 06:31:04 | 10.88% |
| DSP ELSS Tax Saver Fund | 3,737,983 | 1.38 | 243.34 | N/A | N/A | N/A |
| Mirae Asset Midcap Fund | 3,571,092 | 1.26 | 232.48 | 3,471,992 | 2026-01-25 01:13:53 | 2.85% |
| DSP Large & Mid Cap Fund | 3,369,970 | 1.25 | 219.39 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 3,273,806 | 1.31 | 213.12 | 1,811,685 | 2025-12-08 06:31:04 | 80.71% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 12.35 | 12.71 | 11.59 | 9.94 | 10.18 |
| Diluted EPS (Rs.) | 12.34 | 12.69 | 11.51 | 9.82 | 10.11 |
| Cash EPS (Rs.) | 23.07 | 23.28 | 20.70 | 17.60 | 16.98 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 117.44 | 105.92 | 90.13 | 82.28 | 70.53 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 117.44 | 105.92 | 90.13 | 82.28 | 70.53 |
| Revenue From Operations / Share (Rs.) | 90.49 | 86.78 | 79.54 | 64.97 | 54.61 |
| PBDIT / Share (Rs.) | 27.67 | 27.49 | 25.04 | 21.18 | 18.41 |
| PBIT / Share (Rs.) | 16.92 | 16.89 | 15.91 | 13.45 | 11.55 |
| PBT / Share (Rs.) | 16.40 | 15.44 | 14.79 | 12.09 | 11.73 |
| Net Profit / Share (Rs.) | 12.33 | 12.69 | 11.57 | 9.88 | 10.12 |
| NP After MI And SOA / Share (Rs.) | 12.33 | 12.69 | 11.57 | 9.88 | 10.12 |
| PBDIT Margin (%) | 30.57 | 31.67 | 31.48 | 32.59 | 33.71 |
| PBIT Margin (%) | 18.69 | 19.46 | 20.00 | 20.70 | 21.14 |
| PBT Margin (%) | 18.11 | 17.79 | 18.59 | 18.60 | 21.48 |
| Net Profit Margin (%) | 13.62 | 14.61 | 14.54 | 15.19 | 18.53 |
| NP After MI And SOA Margin (%) | 13.62 | 14.61 | 14.54 | 15.19 | 18.53 |
| Return on Networth / Equity (%) | 10.49 | 11.97 | 12.83 | 12.00 | 14.35 |
| Return on Capital Employeed (%) | 12.61 | 13.56 | 13.75 | 12.43 | 12.31 |
| Return On Assets (%) | 7.30 | 8.29 | 7.96 | 7.11 | 8.29 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.13 | 0.16 | 0.18 |
| Total Debt / Equity (X) | 0.02 | 0.03 | 0.15 | 0.23 | 0.27 |
| Asset Turnover Ratio (%) | 0.56 | 0.58 | 0.55 | 0.49 | 0.48 |
| Current Ratio (X) | 1.64 | 1.71 | 2.04 | 1.79 | 1.59 |
| Quick Ratio (X) | 1.53 | 1.50 | 1.76 | 1.65 | 1.54 |
| Inventory Turnover Ratio (X) | 18.49 | 3.06 | 3.52 | 6.45 | 13.01 |
| Dividend Payout Ratio (NP) (%) | 10.13 | 9.86 | 8.63 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 5.41 | 5.37 | 4.82 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 89.87 | 90.14 | 91.37 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 94.59 | 94.63 | 95.18 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 20.97 | 23.41 | 22.24 | 35.22 | 26.58 |
| Interest Coverage Ratio (Post Tax) (X) | 9.74 | 12.04 | 11.27 | 18.70 | 14.35 |
| Enterprise Value (Cr.) | 28558.13 | 27786.54 | 23908.84 | 24195.45 | 21863.70 |
| EV / Net Operating Revenue (X) | 7.84 | 7.96 | 7.49 | 9.29 | 10.01 |
| EV / EBITDA (X) | 25.64 | 25.15 | 23.78 | 28.50 | 29.69 |
| MarketCap / Net Operating Revenue (X) | 8.02 | 8.09 | 7.47 | 9.19 | 9.95 |
| Retention Ratios (%) | 89.86 | 90.13 | 91.36 | 0.00 | 0.00 |
| Price / BV (X) | 6.18 | 6.63 | 6.60 | 7.25 | 7.70 |
| Price / Net Operating Revenue (X) | 8.02 | 8.09 | 7.47 | 9.19 | 9.95 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Syngene International Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 12.35. This value is within the healthy range. It has decreased from 12.71 (Mar 24) to 12.35, marking a decrease of 0.36.
- For Diluted EPS (Rs.), as of Mar 25, the value is 12.34. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.34, marking a decrease of 0.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 23.07, marking a decrease of 0.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 90.49. It has increased from 86.78 (Mar 24) to 90.49, marking an increase of 3.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 27.67. This value is within the healthy range. It has increased from 27.49 (Mar 24) to 27.67, marking an increase of 0.18.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.92. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 16.92, marking an increase of 0.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 16.40. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.40, marking an increase of 0.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
- For PBDIT Margin (%), as of Mar 25, the value is 30.57. This value is within the healthy range. It has decreased from 31.67 (Mar 24) to 30.57, marking a decrease of 1.10.
- For PBIT Margin (%), as of Mar 25, the value is 18.69. This value is within the healthy range. It has decreased from 19.46 (Mar 24) to 18.69, marking a decrease of 0.77.
- For PBT Margin (%), as of Mar 25, the value is 18.11. This value is within the healthy range. It has increased from 17.79 (Mar 24) to 18.11, marking an increase of 0.32.
- For Net Profit Margin (%), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 10. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.62. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.49. This value is below the healthy minimum of 15. It has decreased from 11.97 (Mar 24) to 10.49, marking a decrease of 1.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.61. This value is within the healthy range. It has decreased from 13.56 (Mar 24) to 12.61, marking a decrease of 0.95.
- For Return On Assets (%), as of Mar 25, the value is 7.30. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 7.30, marking a decrease of 0.99.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.64. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.64, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 1.50 (Mar 24) to 1.53, marking an increase of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 18.49. This value exceeds the healthy maximum of 8. It has increased from 3.06 (Mar 24) to 18.49, marking an increase of 15.43.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.13. This value is below the healthy minimum of 20. It has increased from 9.86 (Mar 24) to 10.13, marking an increase of 0.27.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.41. This value is below the healthy minimum of 20. It has increased from 5.37 (Mar 24) to 5.41, marking an increase of 0.04.
- For Earning Retention Ratio (%), as of Mar 25, the value is 89.87. This value exceeds the healthy maximum of 70. It has decreased from 90.14 (Mar 24) to 89.87, marking a decrease of 0.27.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.59. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.59, marking a decrease of 0.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.97. This value is within the healthy range. It has decreased from 23.41 (Mar 24) to 20.97, marking a decrease of 2.44.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.74. This value is within the healthy range. It has decreased from 12.04 (Mar 24) to 9.74, marking a decrease of 2.30.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28,558.13. It has increased from 27,786.54 (Mar 24) to 28,558.13, marking an increase of 771.59.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.84. This value exceeds the healthy maximum of 3. It has decreased from 7.96 (Mar 24) to 7.84, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 25.64. This value exceeds the healthy maximum of 15. It has increased from 25.15 (Mar 24) to 25.64, marking an increase of 0.49.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
- For Retention Ratios (%), as of Mar 25, the value is 89.86. This value exceeds the healthy maximum of 70. It has decreased from 90.13 (Mar 24) to 89.86, marking a decrease of 0.27.
- For Price / BV (X), as of Mar 25, the value is 6.18. This value exceeds the healthy maximum of 3. It has decreased from 6.63 (Mar 24) to 6.18, marking a decrease of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syngene International Ltd:
- Net Profit Margin: 13.62%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.61% (Industry Average ROCE: 48.42%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.49% (Industry Average ROE: 7.44%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.74
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.53
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 53.5 (Industry average Stock P/E: 39.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.62%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Biocon SEZ, Biocon Park, Bengaluru Karnataka 560099 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Kiran Mazumdar Shaw | Non Executive Chairman |
| Mr. Peter Bains | Managing Director & CEO |
| Prof. Catherine Rosenberg | Non Executive Director |
| Ms. Vinita Bali | Lead Independent Director |
| Mr. Nilanjan Roy | Independent Director |
| Dr. Kush Parmar | Independent Director |
| Ms. Sharmila Abhay Karve | Independent Director |
| Dr. Vijay Kuchroo | Independent Director |
| Mr. Manja Boerman | Independent Director |
FAQ
What is the intrinsic value of Syngene International Ltd?
Syngene International Ltd's intrinsic value (as of 26 January 2026) is ₹549.13 which is 0.94% higher the current market price of ₹544.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹21,912 Cr. market cap, FY2025-2026 high/low of ₹795/539, reserves of ₹4,332 Cr, and liabilities of ₹6,542 Cr.
What is the Market Cap of Syngene International Ltd?
The Market Cap of Syngene International Ltd is 21,912 Cr..
What is the current Stock Price of Syngene International Ltd as on 26 January 2026?
The current stock price of Syngene International Ltd as on 26 January 2026 is ₹544.
What is the High / Low of Syngene International Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Syngene International Ltd stocks is ₹795/539.
What is the Stock P/E of Syngene International Ltd?
The Stock P/E of Syngene International Ltd is 53.5.
What is the Book Value of Syngene International Ltd?
The Book Value of Syngene International Ltd is 118.
What is the Dividend Yield of Syngene International Ltd?
The Dividend Yield of Syngene International Ltd is 0.23 %.
What is the ROCE of Syngene International Ltd?
The ROCE of Syngene International Ltd is 13.5 %.
What is the ROE of Syngene International Ltd?
The ROE of Syngene International Ltd is 10.5 %.
What is the Face Value of Syngene International Ltd?
The Face Value of Syngene International Ltd is 10.0.